Jack Sobel, MD
Infectious Disease · Detroit, MINPI 1184664088
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (52.7%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. Mycovia Pharmaceuticals, Inc. accounts for 73.2% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $13,506, more than ten times the $500 reported in 2020. Among infectious disease clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 13 payments — averaging $1402.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mycovia Pharmaceuticals, Inc.$13K
- Scynexis, Inc.$2K
- Biofire Diagnostics, LLC$2K
- AMAG Pharmaceuticals, Inc.$500
- New American Therapeutics, Inc.$500
- Melinta Therapeutics, LLC$119
- plus $34 from 1 others
Across 4 payments — averaging $5470.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Scynexis, Inc.$22K
What the payments were for
- Consulting fees$7,52041%
- Speaking & faculty fees$7504%
- Travel & lodging$9,60353%
- Food & beverage$3642%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mycovia Pharmaceuticals, Inc. | 3 | $13,353 |
| Scynexis, Inc. | 2 | $2,210 |
| Biofire Diagnostics, LLC | 4 | $1,520 |
| AMAG Pharmaceuticals, Inc. | 1 | $500 |
| New American Therapeutics, Inc. | 1 | $500 |
| Melinta Therapeutics, LLC | 1 | $119 |
| Dendreon Pharmaceuticals LLC | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vivjoa$13,353
- Film Array$760
- FilmArray$760
- Rezzayo$119
How this compares
$18,237 in reported general payments places this provider in the 90th percentile of 257 infectious disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clindamycin Phosphate | 41 | $2,931 |
| Estradiol | 26 | $2,559 |
| YuvafemEstradiol | 13 | $1,944 |
| Nystatin-TriamcinoloneNystatin/Triamcinolone Acet | 28 | $919 |
| Clobetasol Propionate | 24 | $883 |
| Fluconazole | 37 | $772 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Detroit
- Teena ChopraDetroit$328K
- Indira BrarDetroit$323K
- Rodger MacarthurDetroit$150K
- Pranatharthi ChandrasekarDetroit$71K
- Mayur RameshDetroit$30K
- Marcus ZervosDetroit$26K
- Smitha GudipatiDetroit$16K
- Ronaldo SupenaDetroit$14K
- Wasif HafeezDetroit$5K
- Nicholas YaredDetroit$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.